a Exploratory single center and b validation multi-center cohorts comparing serum PTX3 levels in patients with PDAC and those with non-neoplastic pancreatico-biliary disease and healthy individuals (control). c Comparison of serum PTX3 levels between patients with PDAC and those with other pancreatic diseases, gallstones and healthy people. Comparison of d serum PTX3, e CA19-9 and f CEA levels between patients with PDAC and those with IPMN or chronic pancreatitis. g Receiver operating characteristic (ROC) curve for PTX3, CA19-9 and CEA. The AUC for PTX3 is 91%, with a cut-off value of 4.35 ng/mL, sensitivity for pancreatic cancer is 86%, specificity 86%, and positive predictive value 97.5%. PTX3 ROC curve was generated by comparing PDAC vs. healthy while CA19.9 and CEA curves were generated by comparing PDAC vs. non-malignant pancreatico-biliary conditions (as data from healthy individuals was not available). Serum PTX3, CEA and CA19-9 levels from healthy volunteers (historical data) are depicted with dotted line. a–f Summary data are expressed as median and interquartile range. Each data-point is a patient, derived from a median value of three to four PTX3 replicates, but single CA19-9 and CEA measurement. a, b Mann–Whitney U test; c–f Kruskal–Wallis test and Dunn’s multiple comparisons test; **P < 0.01, ***P < 0.001, ****P < 0.0001.
展开▼
机译：探索性单中心和B验证多中心队列比较PDAC患者患者的血清PTX3水平和具有非肿瘤胰腺 - 胆道疾病和健康个体（对照）的患者。 PDAC患者血清PTX3水平与其他胰腺疾病，胆结石和健康人群的比较。 PDAC患者与具有IPMN或慢性胰腺炎患者患者的D血清PTX3，E CA19-9和F CEA水平的比较。 G接收器操作特征（ROC）PTX3，CA19-9和CEA曲线。 PTX3的AUC为91％，截止值为4.35ng / ml，胰腺癌的敏感性为86％，特异性86％，阳性预测值97.5％。通过比较PDAC与非恶性胰腺 - 胆道条件（作为来自健康个体的数据而产生Ca19.9和CEA曲线而产生PTX3 ROC曲线。来自健康志愿者（历史数据）的血清PTX3，CEA和CA19-9级别用虚线描绘。 A-F摘要数据表示为中位数和间隔率范围。每个数据点是患者，从中中值为3到四个PTX3复制，但单个CA19-9和CEA测量。 A，B Mann-Whitney U Test; C-F Kruskal-Wallis测试和Dunn的多重比较测试; ** P <0.01，*** P <0.001，**** P <0.0001。
展开▼
